Apairofclinicaltrials,conductedinpartattheUniversityofNorthCarolinaatChapel1Hill,foundthattwoweeksoftreatmentwithrifaximin（利福昔明）providessignificantreliefofirritable2bowel3syndrome4（肠道易激综合症）symptomsincludingbloating（膨胀）,abdominal5painandlooseorwatery6stools.Inaddition,thestudiesfoundthatthebenefitsoftreatmentwithrifaximin(brandname:Xifaxan)persistedfor10weeksafterpatientsstoppedtakingthebroad-spectrumantibiotic7,saidYehudaRingel,MD,anassociateprofessorofmedicineintheUNCSchoolofMedicineandaco-authorofthestudies,whicharepublishedintheJan.6,issueoftheNewEnglandJournalofMedicine.
"Theseresultssupporttheideathatintestinal8（肠的）microbiotaorgut9bacteriamaybeanunderlying10causeofIBS,andalteringgutbacteriabytreatmentwithrifaximinappearstobeaneffectivewayofprovidingrelieftothosewhosufferfromIBSsymptoms,"Dr.Ringelsaid.
FirstauthorofthestudiesisMarkPimentel,MDofCedars-SinaiMedicalCenterinLosAngeles.ThecorrespondingauthorisWilliamP.Forbes,PharmD,ofSalixPharmaceuticals11ofMorrisville,N.C.,whichmakesthedrugandfundedthestudies.
Thetwostudies,knownasTARGET1andTARGET2,wereconductedinparallelfromJunethroughJune.Inthestudies,atotalof1,patientswhohadirritablebowelsyndrome(IBS)withoutconstipation（便秘）wereenrolled12atoneofstudysitesintheU.S.andCanada.Allwererandomizedtoreceivethestudydruginmilligramdoses,threetimesdailyfortwoweeks,orplacebo13.Allwerethenfollowedforanadditional10weeks.
Duringthefirstfourweeksaftertreatment,40.7percentofthepatientsintherifaximingroupreportedadequatereliefofglobalIBSsymptoms,丹芪偏瘫胶囊 零售 价格 元北京中科皮肤病医院
转载请注明：http://www.vzigi.com/zljb/6190.html
